Comparing the Quality of Life in Patients With Multiple Sclerosis Consuming Fingolimod and Cinnovex

Background: Multiple Sclerosis (MS) is a chronic demyelinating, inflammatory, and degenerative disease of the central nervous system. MS gradually limits and deteriorates the patients’ quality of life. Objectives: This study aimed to evaluate and compare the quality of life in patients with MS consu...

Full description

Bibliographic Details
Main Authors: Alia Saberi, Hamidreza Hatamian, Amirreza Ghayeghran, Fatemeh Mola Hosseini, Sama Noroozi Guilandehi, Sajjad Rezaei, Fatemeh Shafaei
Format: Article
Language:English
Published: Guilan University of Medical Sciences 2019-11-01
Series:Caspian Journal of Neurological Sciences
Subjects:
Online Access:http://cjns.gums.ac.ir/article-1-291-en.html
id doaj-33adc53f06964337ae5ca03018212067
record_format Article
spelling doaj-33adc53f06964337ae5ca030182120672020-11-24T22:00:00ZengGuilan University of Medical SciencesCaspian Journal of Neurological Sciences2423-48182423-48182019-11-0154151160Comparing the Quality of Life in Patients With Multiple Sclerosis Consuming Fingolimod and CinnovexAlia Saberi0Hamidreza Hatamian1Amirreza Ghayeghran2Fatemeh Mola Hosseini3Sama Noroozi Guilandehi4Sajjad Rezaei5Fatemeh Shafaei6 Neuroscience Research Center, Department of Neurology, Poursina Hospital, Guilan University of Medical Sciences, Rasht, Iran Department of Neurology, Poursina Hospital, Guilan University of Medical Sciences, Rasht, Iran Department of Neurology, Poursina Hospital, Guilan University of Medical Sciences, Rasht, Iran Department of Neurology, Poursina Hospital, Guilan University of Medical Sciences, Rasht, Iran School of Medicine, Guilan University of Medical Sciences, Rasht, Iran Department of Psychology, University of Guilan, Rasht, Iran Neuroscience Research Center, Poursina Hospital, Guilan University of Medical Sciences, Rasht, Iran Background: Multiple Sclerosis (MS) is a chronic demyelinating, inflammatory, and degenerative disease of the central nervous system. MS gradually limits and deteriorates the patients’ quality of life. Objectives: This study aimed to evaluate and compare the quality of life in patients with MS consuming Fingolimod and Cinnovex. Materials & Methods: In an analytical cross-sectional study, 106 patients with Relapsing-Remitting MS (RRMS) referred to specialized neurology clinics of Guilan University of Medical Sciences were selected for the study using a convenience sampling method (52 patients consuming Fingolimod and 54 patients consuming Cinnovex). Then, we collected their demographic information and medical profile. The patients were assessed by the Hamburg quality of life questionnaire in MS. The obtained data were analyzed in SPSS V. 22 using the Chi-square test, independent t-test, Mann-Whitney U, one-way and  multivariate analysis of covariance. Results: There was a significant difference between the two groups in terms of age, number of attacks in the last 6 months, and educational level (P<0.05). After controlling confounding variables, it was found that consumers of Fingolimod had a better quality of life. At the subscales level, this difference was significant only in the mood dimension (F=6.931, P=0.011, η=0.12). Conclusion: Patients consuming Fingolimod reported a better quality of life compared to consumers of Cinnovex. This improvement was mainly found in mood scores.http://cjns.gums.ac.ir/article-1-291-en.htmlmultiple sclerosis (ms)quality of life (qol)fingolimod hydrochloride
collection DOAJ
language English
format Article
sources DOAJ
author Alia Saberi
Hamidreza Hatamian
Amirreza Ghayeghran
Fatemeh Mola Hosseini
Sama Noroozi Guilandehi
Sajjad Rezaei
Fatemeh Shafaei
spellingShingle Alia Saberi
Hamidreza Hatamian
Amirreza Ghayeghran
Fatemeh Mola Hosseini
Sama Noroozi Guilandehi
Sajjad Rezaei
Fatemeh Shafaei
Comparing the Quality of Life in Patients With Multiple Sclerosis Consuming Fingolimod and Cinnovex
Caspian Journal of Neurological Sciences
multiple sclerosis (ms)
quality of life (qol)
fingolimod hydrochloride
author_facet Alia Saberi
Hamidreza Hatamian
Amirreza Ghayeghran
Fatemeh Mola Hosseini
Sama Noroozi Guilandehi
Sajjad Rezaei
Fatemeh Shafaei
author_sort Alia Saberi
title Comparing the Quality of Life in Patients With Multiple Sclerosis Consuming Fingolimod and Cinnovex
title_short Comparing the Quality of Life in Patients With Multiple Sclerosis Consuming Fingolimod and Cinnovex
title_full Comparing the Quality of Life in Patients With Multiple Sclerosis Consuming Fingolimod and Cinnovex
title_fullStr Comparing the Quality of Life in Patients With Multiple Sclerosis Consuming Fingolimod and Cinnovex
title_full_unstemmed Comparing the Quality of Life in Patients With Multiple Sclerosis Consuming Fingolimod and Cinnovex
title_sort comparing the quality of life in patients with multiple sclerosis consuming fingolimod and cinnovex
publisher Guilan University of Medical Sciences
series Caspian Journal of Neurological Sciences
issn 2423-4818
2423-4818
publishDate 2019-11-01
description Background: Multiple Sclerosis (MS) is a chronic demyelinating, inflammatory, and degenerative disease of the central nervous system. MS gradually limits and deteriorates the patients’ quality of life. Objectives: This study aimed to evaluate and compare the quality of life in patients with MS consuming Fingolimod and Cinnovex. Materials & Methods: In an analytical cross-sectional study, 106 patients with Relapsing-Remitting MS (RRMS) referred to specialized neurology clinics of Guilan University of Medical Sciences were selected for the study using a convenience sampling method (52 patients consuming Fingolimod and 54 patients consuming Cinnovex). Then, we collected their demographic information and medical profile. The patients were assessed by the Hamburg quality of life questionnaire in MS. The obtained data were analyzed in SPSS V. 22 using the Chi-square test, independent t-test, Mann-Whitney U, one-way and  multivariate analysis of covariance. Results: There was a significant difference between the two groups in terms of age, number of attacks in the last 6 months, and educational level (P<0.05). After controlling confounding variables, it was found that consumers of Fingolimod had a better quality of life. At the subscales level, this difference was significant only in the mood dimension (F=6.931, P=0.011, η=0.12). Conclusion: Patients consuming Fingolimod reported a better quality of life compared to consumers of Cinnovex. This improvement was mainly found in mood scores.
topic multiple sclerosis (ms)
quality of life (qol)
fingolimod hydrochloride
url http://cjns.gums.ac.ir/article-1-291-en.html
work_keys_str_mv AT aliasaberi comparingthequalityoflifeinpatientswithmultiplesclerosisconsumingfingolimodandcinnovex
AT hamidrezahatamian comparingthequalityoflifeinpatientswithmultiplesclerosisconsumingfingolimodandcinnovex
AT amirrezaghayeghran comparingthequalityoflifeinpatientswithmultiplesclerosisconsumingfingolimodandcinnovex
AT fatemehmolahosseini comparingthequalityoflifeinpatientswithmultiplesclerosisconsumingfingolimodandcinnovex
AT samanorooziguilandehi comparingthequalityoflifeinpatientswithmultiplesclerosisconsumingfingolimodandcinnovex
AT sajjadrezaei comparingthequalityoflifeinpatientswithmultiplesclerosisconsumingfingolimodandcinnovex
AT fatemehshafaei comparingthequalityoflifeinpatientswithmultiplesclerosisconsumingfingolimodandcinnovex
_version_ 1725845990036996096